Two siblings affected by type III von Willebrand’s disease with precipitating alloantibodies against von Willebrand’s factor (vWF) and not susceptible to treatment with factor VIII/ vWF concentrates received recombinant activated factor VII for oral surgery. This therapy, combined with antifibrinolytic drugs and local application of fibrin glue, seems to be effective and safe. It may be considered a promising approach to the management of this rare condition. © 1996 S. Karger AG, Basel.
Use of recombinant factor vila (novoseven®) in the treatment of two patients with type iii von willebrand’s disease and an inhibitor against von willebrand factor
Mangini F.;Inchingolo F.
1996-01-01
Abstract
Two siblings affected by type III von Willebrand’s disease with precipitating alloantibodies against von Willebrand’s factor (vWF) and not susceptible to treatment with factor VIII/ vWF concentrates received recombinant activated factor VII for oral surgery. This therapy, combined with antifibrinolytic drugs and local application of fibrin glue, seems to be effective and safe. It may be considered a promising approach to the management of this rare condition. © 1996 S. Karger AG, Basel.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
